Dr. Falk Pharma GmbH vs. Ellodi Pharmaceuticals LP

Explore the PTAB proceeding IPR2025-00055 filed by Dr. Falk Pharma GmbH on 2024-10-24. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2025-00055

Filing Date

2024-10-24

Accorded Filing Date

2024-10-24

Institution Decision Date

2025-06-03

Last Modified Date

2026-04-06

Proceeding Type

IPR

Termination Date

2026-01-26

Trial Status

Terminated-Adverse Judgment

Parties & Counsel

Petitioner

Dr. Falk Pharma GmbH

Represented By

Luman, Nathanaelet al

Patent Owner / Respondent

Ellodi Pharmaceuticals LP

Represented By

Sukduang, Sanyaet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1600 - Biotechnology & Organic Chemistry

Patent Information

1 Patent Involved

Respondent Application Number 14294660

Respondent Patent Number 9486407

External Links

Espacenet

Google Patents

Respondent Inventor Stephen PERRETT et al

Respondent Tech Center TC 1600 - Biotechnology & Organic Chemistry

Address and Attorney/Agent Information

31 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name Cooley LLP / Eurand

Customer Number 91543

Address ATTN: Patent Group, 1299 Pennsylvania Avenue, Suite 700, Washington, DC, 20004, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
32289	Frank Pietrantonio	703-456-8567
33885	William Galliani	650-843-5622
34262	C Talbot	703-456-8072
36977	Kevin Zimmer	858-945-8634
41087	Christopher Hutter	703-456-8506
42887	Erik Milch	202-416-5845
43210	Michael Tuscan	202-842-7802
43255	Bonnie Mcleod	202-842-7800
43360	Nan Wu	415-693-2002
44051	Thomas Croft	248-864-5904
50501	Nancy Vashaw	703-456-8000
50834	Cliff Liu	650-843-5852
51793	Mark Hayman	617-951-8440
53087	Tamara Kale	650-779-2245
54092	Jason Fan	407-841- 2343
55854	Scott Weston	617-937-2327
56414	John Mills	571-299-2062
57403	Kyle Pendergrass	858-231-2473
57835	Phillip Morton	703-456-8000
59129	Jeffery Wyzykowski	202-842-7800
59307	David Hopkins	720-566-4063
59855	Steven Tietsworth	858-244-5939
61469	Christopher James	703-456-8539
61689	Margaret Fischofer	703-456-8000
62305	Jennifer Volk	703-456-8575
63322	Eamonn Gardner	858-550-6086
64349	Andrew Keith	202-842-7800
65210	Christina Macdougall	415-442-1277
66418	Jonathan Cousin	202-842-7800
70211	Jason Valentine	202-728-7157
L0625	Yi Wang	202-728-7128

Proceeding Documents

130

3101

Ex. 3101 Email correspondence Exhibit

2026-01-29 FILING PARTY: BOARD

Download

DECISION Granting Patent Owner’s Motion to Terminate and Request for Adverse Judgment After Institution of Trial 37 C.F.R. §§ 42.72, 42.73(b) ADVRSJUDG

2026-01-26 FILING PARTY: BOARD

Download

Petitioner's Request for Oral Argument OTHER

2026-01-20 FILING PARTY: PETITIONER

Download

Patent Owner's Updated Exhibit List NOTICE

2026-01-20 FILING PARTY: PATENT OWNER

Download

Patent Owner's Motion to Terminate and Request for Adverse Judgment MOTION

2026-01-20 FILING PARTY: PATENT OWNER

Download

Dr. Falk Pharma GmbH vs. Ellodi Pharmaceuticals LP

Proceeding Overview

Parties & Counsel

Petitioner

Dr. Falk Pharma GmbH

Represented By

Patent Owner / Respondent

Ellodi Pharmaceuticals LP

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Ex. 3101 Email correspondence Exhibit

DECISION Granting Patent Owner’s Motion to Terminate and Request for Adverse Judgment After Institution of Trial 37 C.F.R. §§ 42.72, 42.73(b) ADVRSJUDG

Petitioner's Request for Oral Argument OTHER

Patent Owner's Updated Exhibit List NOTICE

Patent Owner's Motion to Terminate and Request for Adverse Judgment MOTION

Disclaimer of U.S. Patent No. 9,486,407 Exhibit

Order: Authorizing Patent Owner’s Motion to Terminate ORDER

Ex. 3001 Attorney Correspondence Exhibit

Prosecution History [Excerpts] of U.S. Application No. 14/294,660 which issued as U.S. 9,486,407 Exhibit

Narmada et al., “Formulation, evaluation and optimization of fast dissolving tablets containing amlodipine besylate by sublimation method,” ARS Pharmaceutica, 50:129-144 (2009) Exhibit

U.S. Federal Trade Commission (FTC), To Promote Innovation: The Proper Balance of Competition and Patent Law and Policy, Chapter 4: Competition Perspectives on Substantive Standards of Patentability (2003) Exhibit

Petitioner's Updated Exhibit List NOTICE

U.S. Publication No. US20110189299 to Okubo and Davies et al. Exhibit

Declaration of Alan F. Parr, Pharm.D., Ph.D. supporting Petitioner Reply for U.S. Patent Nos. 10,632,069, 11,246,828, and 9,486,407 Exhibit

U.S. Patent Publication No. 20080132535 to Singh et al. Exhibit

2015-09-04 Assignment of U.S. Patent Application No. 10/827,106 (which published as Venkatesh, EX1020) to Adare Pharmaceuticals, Inc. recorded at Reel 036554, Frame 0829 Exhibit

2025-07-02 Deposition transcript of Dr. Martyn Davies in IPR2024- 01197 Exhibit

CLARITIN® (loratadine) FDA-approved package insert Exhibit

U.S. Patent No. 8,771,729 to Perrett et al. Exhibit

CLARINEX® (desloratadine) FDA-approved package insert Exhibit

Petitioner's Reply Brief REPLYTOOPP

U.S. Patent No. 7,384,921 to Tang et al. Exhibit

2025-11-19 Deposition transcript of Dr. Martyn Davies in IPR2025- 00052, IPR2025-00054, and IPR2025-00055 Exhibit

ZOFRAN® (ondansetron) FDA-approved package insert Exhibit

2024-10-23 Transcript of Oral Hearing Dismissing Complaint, Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma, Case No. 24-cv- 01392-PTG (E.D. Va) Exhibit

PEPCID® (famotidine) FDA-approved package insert Exhibit

Than, “Individualized Drugs for Individual Needs,” Review of Optometry, 146:38-43 (2009) Exhibit

2021-04-19 Assignment of U.S. Patent Nos. 10,632,069, 9,486,407, and 8,771,729 from Adare Pharmaceuticals US, L.P. to Ellodi Pharmaceuticals, L.P. recorded at Reel 055966, Frame 0658. Exhibit

Judgment Granting Request for Adverse Judgment after Institution of Trial, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2024-01197, Paper 41 (PTAB 2025) Exhibit

U.S. Patent Publication No. 20030124184 to Mezaache et al. Exhibit

Judgment Against Ellodi in Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma GmbH, Case No. 4b O 43/24, Regional Court of Dusseldorf, Germany (Feb. 27, 2025) – Certified English Language Translation Exhibit

International Publication No. WO2003074029 to McEntee et al. Exhibit

Schoepfer et al., “Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis,” Clinical Gastroenterology and Hepatology, 17:1477- 1488 (2019). Exhibit

U.S. Patent Publication No. 20050019393 to Augsburger et al. Exhibit

The American Heritage Dictionary of the English Language, 4th ed., 2000 - Definitions of “disintegrate” and “dissolve” Exhibit

2015-09-18 Assignment of U.S. Patent No. 6,139,865 to Adare Pharmaceuticals, Inc. recorded at Reel 036640, Frame 0591 Exhibit

Khan et al., “Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets,” AAPS PharmSciTech 8:E1-E7 (2007) Exhibit

Judgment Against Ellodi in Ellodi Pharmaceuticals, L.P. v. Dr. Falk Pharma GmbH, Case No. 4b O 43/24, Regional Court of Dusseldorf, Germany (Feb. 27, 2025) – Original German Language Exhibit

U.S. Patent Publication No. 20090022799 to Barman Exhibit

U.S. Patent No. 6,139,865 to Friend et al. Exhibit

International Publication No. WO2009078872 to Martin et al. Exhibit

Decision Granting Instituting of IPR, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2024-01197, Paper 10 (PTAB 2025) Exhibit

Petitioner’s Reply Brief, Dr. Falk Pharma GmbH v. Ellodi Pharmaceuticals, L.P., IPR2024-01197, Paper 20 (PTAB 2025) Exhibit

Comment of the U.S. Federal Trade Commission (FTC), Terminal Disclaimer Practice to Obvoiusate Nonstatutory Double Patenting, PTO-P-2024-0003 (2024) Exhibit

Petitioner's Updated Exhibit List NOTICE

November 3, 2025 Oral Hearing Transcript Regarding IPR2025-00052, IPR2025-00054, IPR2025-00055, and IPR2025-00056 Exhibit

Petitioner's Revised Notice of Deposition of Dr. Martyn Christopher Davies NOTICE

Joint Stipulation to Modify Due Dates 2-3 NOTICE

Order: Conduct of the Proceeding; Extending Word Limit for Reply and Sur-Reply 37 C.F.R. sec. 42.5a ORDER

Petitioner's Notice of Deposition of Dr. Martyn Christopher Davies NOTICE

Petitioner's Updated Mandatory Notice NOTICE

Petitioner's Supplemental Mandatory Notice: Related Matters Section NOTICE

General Order: Related Matters Updates ORDER

Petitioner's Objections to Admissibility of Patent Owner's Evidence OTHER

Memorandum from Director Coke Morgan Stewart to Members of the Patent Trial and Appeal Board re Enforcement and Non-Waiver of 37 C.F.R. § 42.104(B)(4) and Permissible Uses of General Knowledge in Inter Partes Reviews, dated July 31, 2025 Exhibit

Paul J. Sheskey et al., Handbook of Pharmaceutical Excipients (8d. 2017) Exhibit

Miehkle, S. et al., A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eo-sinophilic oesophagitis, Gut 0:1-10 (2015) Exhibit

Transcript of the August 25, 2025 deposition of Alan Parr, Pharm.D. from No. IPR2024-01197 Exhibit

Declaration of Martyn Christopher Davies in Support of Patent Owner’s Response Exhibit

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, Patent and Exclusivity for: N213976, Product 001 Budesonide (Eohilia) Suspension 2mg/10ml Exhibit

M.E. Aulton (Ed.), Pharmaceutics: The Science of Dosage Form Design (2d. 2002) Exhibit

Hahm, H.A., Augsburger, L.L., Ch. 9 Orally Disintegrating Tablets and Related Tablet Formulations Exhibit

“Antrum” Definition, American Medical Dictionary: A Concise and Up-to-Date Guide to Medical Terms (1998) Exhibit

Cordova-Fraga T, Sosa M, Wiechers C, et al., Effects of anatomical position on esophageal transit time: a biomagnetic diagnostic tech­nique. World J Gastroenterol 14:5707–11 (2008) Exhibit

U.S. Patent No. 8,324,192 Exhibit

Cordova-Fraga T, Sosa M, Wiechers C, et al., Effects of anatomical position on esophageal transit time: a biomagnetic diagnostic technique. World J Gastroenterol 14:5707–11 (2008) Exhibit